QQQ   361.72 (-1.30%)
AAPL   164.51 (-1.03%)
MSFT   301.60 (-0.57%)
FB   316.56 (-0.95%)
GOOGL   2,666.15 (-1.34%)
AMZN   3,033.35 (-2.96%)
TSLA   996.27 (+0.06%)
NVDA   241.50 (-3.66%)
BABA   131.03 (+2.58%)
NIO   29.13 (+1.75%)
AMD   121.89 (-4.97%)
CGC   7.56 (-1.05%)
MU   85.07 (-5.48%)
GE   98.25 (-2.36%)
T   27.02 (-0.95%)
F   21.65 (-3.56%)
DIS   147.62 (-1.66%)
AMC   18.07 (-1.36%)
PFE   54.05 (+0.95%)
ACB   4.75 (-2.26%)
BA   214.19 (-1.33%)
QQQ   361.72 (-1.30%)
AAPL   164.51 (-1.03%)
MSFT   301.60 (-0.57%)
FB   316.56 (-0.95%)
GOOGL   2,666.15 (-1.34%)
AMZN   3,033.35 (-2.96%)
TSLA   996.27 (+0.06%)
NVDA   241.50 (-3.66%)
BABA   131.03 (+2.58%)
NIO   29.13 (+1.75%)
AMD   121.89 (-4.97%)
CGC   7.56 (-1.05%)
MU   85.07 (-5.48%)
GE   98.25 (-2.36%)
T   27.02 (-0.95%)
F   21.65 (-3.56%)
DIS   147.62 (-1.66%)
AMC   18.07 (-1.36%)
PFE   54.05 (+0.95%)
ACB   4.75 (-2.26%)
BA   214.19 (-1.33%)
QQQ   361.72 (-1.30%)
AAPL   164.51 (-1.03%)
MSFT   301.60 (-0.57%)
FB   316.56 (-0.95%)
GOOGL   2,666.15 (-1.34%)
AMZN   3,033.35 (-2.96%)
TSLA   996.27 (+0.06%)
NVDA   241.50 (-3.66%)
BABA   131.03 (+2.58%)
NIO   29.13 (+1.75%)
AMD   121.89 (-4.97%)
CGC   7.56 (-1.05%)
MU   85.07 (-5.48%)
GE   98.25 (-2.36%)
T   27.02 (-0.95%)
F   21.65 (-3.56%)
DIS   147.62 (-1.66%)
AMC   18.07 (-1.36%)
PFE   54.05 (+0.95%)
ACB   4.75 (-2.26%)
BA   214.19 (-1.33%)
QQQ   361.72 (-1.30%)
AAPL   164.51 (-1.03%)
MSFT   301.60 (-0.57%)
FB   316.56 (-0.95%)
GOOGL   2,666.15 (-1.34%)
AMZN   3,033.35 (-2.96%)
TSLA   996.27 (+0.06%)
NVDA   241.50 (-3.66%)
BABA   131.03 (+2.58%)
NIO   29.13 (+1.75%)
AMD   121.89 (-4.97%)
CGC   7.56 (-1.05%)
MU   85.07 (-5.48%)
GE   98.25 (-2.36%)
T   27.02 (-0.95%)
F   21.65 (-3.56%)
DIS   147.62 (-1.66%)
AMC   18.07 (-1.36%)
PFE   54.05 (+0.95%)
ACB   4.75 (-2.26%)
BA   214.19 (-1.33%)
LON:CLIN

Clinigen Group Share Forecast, Price & News

GBX 905
-3.00 (-0.33%)
(As of 01/20/2022 12:00 AM ET)
Add
Compare
Today's Range
903.50
913
50-Day Range
576.50
935
52-Week Range
541.50
948.05
Volume
1.17 million shs
Average Volume
1.79 million shs
Market Capitalization
£1.21 billion
P/E Ratio
40.58
Dividend Yield
0.84%
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive CLIN News and Ratings via Email

Sign-up to receive the latest news and ratings for Clinigen Group and its competitors with MarketBeat's FREE daily newsletter.


Clinigen Group logo

About Clinigen Group

Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines. The Unlicensed Medicines segment is involved in sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Clinical Services segment packages, supplies, distributes, and manages comparator medicines and services to clinical trials and investigator initiated trials. It offers Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals which work by stopping viruses from multiplying in number; AZEDR for the treatment of adult and pediatric patients; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Drug Delivery
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
1,250
Year Founded
N/A

Sales & Book Value

Annual Sales
£523.60 million
Cash Flow
GBX 62.09 per share
Book Value
GBX 336.10 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
£1.21 billion
Optionable
Not Optionable

Company Calendar

Last Earnings
9/17/2020
Ex-Dividend for 1/4 Dividend
12/02/2021
Dividend Payable
1/04/2022
Today
1/20/2022
Next Earnings (Estimated)
2/21/2022

MarketRank

Overall MarketRank

1.43 out of 5 stars

Analyst Opinion: 1.3Community Rank: 5.0Dividend Strength: 0.8Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Clinigen Group (LON:CLIN) Frequently Asked Questions

Is Clinigen Group a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Clinigen Group in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Clinigen Group stock.
View analyst ratings for Clinigen Group
or view top-rated stocks.

How has Clinigen Group's stock price been impacted by Coronavirus?

Clinigen Group's stock was trading at GBX 657 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CLIN stock has increased by 37.7% and is now trading at GBX 905.
View which stocks have been most impacted by COVID-19
.

When is Clinigen Group's next earnings date?

Clinigen Group is scheduled to release its next quarterly earnings announcement on Monday, February 21st 2022.
View our earnings forecast for Clinigen Group
.

How were Clinigen Group's earnings last quarter?

Clinigen Group plc (LON:CLIN) announced its quarterly earnings data on Thursday, September, 17th. The company reported $65.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $63.50 by $2.10.
View Clinigen Group's earnings history
.

How often does Clinigen Group pay dividends? What is the dividend yield for Clinigen Group?

Clinigen Group announced a dividend on Thursday, September 16th. Investors of record on Thursday, December 2nd will be given a dividend of GBX 5.46 per share on Tuesday, January 4th. This represents a yield of 0.92%. The ex-dividend date of this dividend is Thursday, December 2nd. This is a positive change from Clinigen Group's previous dividend of GBX 2.15. The official announcement can be accessed at this link.
View Clinigen Group's dividend history
.

Is Clinigen Group a good dividend stock?

Clinigen Group pays an annual dividend of GBX 0.08 per share and currently has a dividend yield of 0.84%. The dividend payout ratio of Clinigen Group is 0.34%. This payout ratio is at a healthy, sustainable level, below 75%.
View Clinigen Group's dividend history.

What price target have analysts set for CLIN?

5 brokerages have issued 12-month price objectives for Clinigen Group's stock. Their forecasts range from GBX 650 to GBX 860. On average, they expect Clinigen Group's stock price to reach GBX 740 in the next twelve months. This suggests that the stock has a possible downside of 18.2%.
View analysts' price targets for Clinigen Group
or view top-rated stocks among Wall Street analysts.

Who are Clinigen Group's key executives?

Clinigen Group's management team includes the following people:
  • Mr. Shaun Edward Chilton, CEO & Exec. Director (Age 53, Pay $1.11M)
  • Mr. Nicholas P. Keher, CFO & Exec. Director
  • Mr. Sam Herbert, Chief Operating Officer
  • Matt Parrish, Head of Investor Relations
  • Ms. Amanda Miller, Gen. Counsel & Company Sec.
  • Mr. David Bryant, Director of Corp. Devel.
  • Jessica Archer, Global HR Director
  • Mr. Mark Corbett, Managing Director of Global Access Division
  • Mr. Johannes Willemse, Chief Commercial Officer (Age 53)
  • Mr. Ivo Timmermans M.D., MBA, Chief Medial Officer (Age 61)

What other stocks do shareholders of Clinigen Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Clinigen Group investors own include Comerica (CMA), Honda Motor (HMC), Advanced Accelerator Applications (AAAP), Albemarle (ALB), First Hawaiian (FHB), Landec (LNDC), NII (NIHD), RTI International Metals (RTI), General Electric (GE) and NetApp (NTAP).

What is Clinigen Group's stock symbol?

Clinigen Group trades on the London Stock Exchange (LON) under the ticker symbol "CLIN."

How do I buy shares of Clinigen Group?

Shares of CLIN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Clinigen Group's stock price today?

One share of CLIN stock can currently be purchased for approximately GBX 905.

How much money does Clinigen Group make?

Clinigen Group has a market capitalization of £1.21 billion and generates £523.60 million in revenue each year.

How many employees does Clinigen Group have?

Clinigen Group employs 1,250 workers across the globe.

What is Clinigen Group's official website?

The official website for Clinigen Group is www.clinigengroup.com.

Where are Clinigen Group's headquarters?

How can I contact Clinigen Group?

Clinigen Group's mailing address is Pitcairn House Crown Square, First Avenue, STAFFORDSHIRE, DE14 2WW, United Kingdom. The company can be reached via phone at +44-1283-495010.


This page was last updated on 1/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.